
Why Summer Promotions Could Boost Apparel's Recovery
(Photo by HENRY NICHOLLS / AFP) (Photo by HENRY NICHOLLS/AFP via Getty Images)
When it comes to clothing, this heightened awareness can lead to a whole host of behavioral shifts. In the first quarter of this year, two-thirds of consumers said they would either trade down, delay, or altogether skip their apparel purchase due to potential price increases from tariffs. While price increases are nothing new in the apparel industry — in fact, prices have been increasing for the past three years — what was once a tolerance for price increases is transforming, and consumer behavior is changing along with it.
From Want to Need: The Behavioral Shift
So, why is it that consumers are expecting to change their apparel shopping behavior now, when they've been feeling price pressures for the past few years? The answer lies in evolving consumer needs. In the one to two years following the COVID-19 pandemic, consumers ravenously replenished their wardrobes. It happened in waves that aligned with consumers' needs: first it was the basics like bras and underwear, next activewear, and then swimwear and tailored pieces. When inflation hit consumers' wallets, they didn't have to trade down in apparel and hunt for promotions because they had recently replenished their wardrobes. They either bought something if they wanted it, or they didn't buy at all.
What's different now is the replenishment cycle has gone full circle and the 'need' factor has returned. Consumers have gone a few years without replenishing some of their must-have items, causing a fundamental change in shopping behavior. The shift from "want" to "need" is causing more of a focus on price.
The Summer Promotional Opportunity
As we enter the season of summer promotions across retail, apparel has the chance to be one of the better performing categories. Industries like beauty and tech often dominate during these timeframes as consumers pinpoint specific deals for desired items. However, we may see more of an opportunity for apparel as consumers wait until the price is right, or at least more desirable, to replenish basics, activewear, or other put-off categories.
We have been seeing a bit of a shift toward promotions in recent weeks. In the 13 weeks ending May 31, the average promotional depth in apparel remained relatively flat, but the sales of promoted items grew by 2%, compared to last year, outpacing sales of full-price items.
We are seeing sales of promotional items increase for replenishment categories like underwear, sweatshirts, and sleepwear. These upcoming promotional weeks remain an opportunity for seasonal apparel. "Buy now, wear now" has shifted to "need now, buy now," which not only aligns with weather needs, but lifestyle needs as well. Consumers shopping for an upcoming vacation may buy swimwear a week before, as opposed to the month before.
Kids' apparel, especially, is experiencing increased sales of promotional apparel, with boys' and girls' promotional apparel up 16% and 9%, respectively. This presents a significant opportunity for retailers to highlight seasonal apparel and even get ahead of some back-to-school needs.
The Innovation Imperative
While the opportunity remains, it wasn't too long ago that the apparel industry found itself all too reliant on promotions to move sales. Consumers played promotional chicken with retailers, waiting out for those steep discounts. While promotions will play a role the back half of 2025, it is imperative that the industry doesn't fall into a discount loophole.
The challenge for apparel brands and retailers is striking the right balance: meeting consumers' heightened price sensitivity while maintaining the innovation and newness that drives long-term category growth. Those who can navigate this delicate balance will be best positioned to capture the tariff-aware consumer's attention and wallet share in the months ahead.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Why Google should 'walk away' from Waymo
Needham & Company senior media and internet analyst Laura Martin joins Market Domination with Josh Lipton to explain why Alphabet (GOOG, GOOGL) should ditch Waymo and focus on generative artificial intelligence (AI) instead. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Related videos The £70bn pension tax raid Reeves may not be able to resist 10 shares I wouldn't want to hold in a stock market crash After falling 16% in a day, this stock's on my list of shares to buy in August This FTSE 250 trust is easily beating the global index in 2025. Time to buy? Sign in to access your portfolio
Yahoo
25 minutes ago
- Yahoo
EMCOR Group (EME) Sees EPS Surge as Net Income Climbs to US$241 Million
EMCOR Group recently announced a regular quarterly cash dividend of $0.25 per common share, to be paid on July 31, 2025. This steady dividend approach aligns with the company's robust quarterly performance, which saw net income rise to $241 million and EPS increase substantially year-over-year. Additionally, the ongoing share buyback program has strengthened shareholder returns. Despite the broader market's moderate growth of 1.4% over the past week and 17% over the past year, EMCOR's notable share repurchases and solid financial outcomes appear to have amplified investor confidence, contributing to the company's impressive 55% stock price surge last quarter. We've spotted 1 risk for EMCOR Group you should be aware of. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. EMCOR Group's recent announcement of a quarterly dividend and the implementation of its share buyback program underline its commitment to enhancing shareholder returns. Despite a potential downside to the current share price of US$635.06, which exceeds the consensus analyst price target of US$549.57 by 13.46%, these actions could continue to buoy investor confidence. The company's performance over the past five years, with a total return exceeding 844.60%, showcases its robust long-term trajectory. In the last year, EMCOR's share performance exceeded both the broader market's 17.2% and the US Construction industry's 54.2% return, highlighting its strong standing relative to peers. The successful integration of acquisitions and strategic diversification into sectors like data centers and healthcare is anticipated to impact future revenue positively. This, coupled with operational efficiencies and strong revenue collaboration, may reinforce earnings projections. However, EMCOR's earnings forecasts of a 6.2% annual growth rate lag behind the broader market's 14.9% forecast, which could present challenges in meeting broader industry expectations. The company's impressive share price rise of 55% last quarter signals optimism, though its current value being above the target may indicate overvaluation concerns. Nevertheless, the consistent cash flow and healthy margins underscore its potential resilience against margin pressures, supply chain challenges, and other economic uncertainties. As analysts estimate revenue growth to 7.9% annually over the next three years, any tangible improvement in operational metrics could shift the valuation outlook positively. Unlock comprehensive insights into our analysis of EMCOR Group stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include EME. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@